Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02568033 |
Recruitment Status : Unknown
Verified July 2016 by The Cooper Health System.
Recruitment status was: Recruiting
First Posted : October 5, 2015
Last Update Posted : January 31, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Small Cell Lung Cancer | Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Docetaxel Drug: Paclitaxel Radiation: stereotactic radiosurgery | Early Phase 1 |
Current standard of care for treatment of locally advanced (unresectable stage II and all of stage III) non-small cell lung cancer (NSCLC) is chemo-radiation which consists of 7 weeks of radiation and chemotherapy given at a reduced dose (as opposed to systemic dose when chemotherapy given by itself). While outcomes have improved over time they remain humbling, with current approaches associated with overall poor results both in terms of local (30% of patients have local failure) and distant control (40% of patients have distant failure) with a median overall survival of 17 months.
This study is evaluating treatment with full dose chemotherapy and stereotactic body radiotherapy (SBRT). SBRT uses high doses of radiation in a very precise and conformal manner, the number of treatments are much reduced versus conventional radiation (SBRT would be able to be completed in 2 weeks or less). The biologically effective dose of SBRT is much higher than that of conventional radiation; despite being a shorter number of treatments the effective radiation dose is higher. SBRT would be completed in 2 weeks and since radiation would be completed in a shorter time span, would allow patients to have higher (systemic) chemotherapy doses.
The purpose of this study is to explore SBRT in addition to systemic doses of chemotherapy in the treatment of locally advanced NSCLC.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 22 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001) |
Study Start Date : | October 2013 |
Estimated Primary Completion Date : | October 2017 |
Estimated Study Completion Date : | October 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Chemotherapy: for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions Schedule is: 2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy. |
Drug: Pemetrexed
Other Name: Alimta Drug: Carboplatin Drug: Cisplatin Drug: Docetaxel Other Name: taxotere Drug: Paclitaxel Other Name: taxol Radiation: stereotactic radiosurgery Other Name: CK, cyberknife, cyber knife |
- Disease free progression [ Time Frame: 4-6 months ]Local control will be evaluated at end of treatment (4-6 months) and then at regular follow up intervals.
- Toxicity (Treatment related side effects) [ Time Frame: 4-5 months ]Treatment related side effects will be monitored

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Nonsmall cell lung cancer (NSCLC) (any histology)
- unresectable stage II
- Stage III
- Tumor less than 8 cm
- Karnofsky performance scale (KPS) of 50 or better
- Three or fewer mediastinal or hilar lymph nodes
Exclusion criteria
- Small cell lung cancer (SCLC)
- Stage I and stage IV patients
- Stage II patients eligible for surgical resection
- Concurrent severe disease that the treating physician feels will interfere with therapy this can include significant cardiovascular or pulmonary disease.
- KPS 40 or less (bed bound)
- Tumor size greater than 8 cm
- Inability to safely treat target lesions (at discretion of treating physician, this would most likely be secondary to not being able to place fiducial markers for tracking)
- Four or more medisatinal or hilar lymph nodes

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02568033
Contact: Kimberly Krieger | 856-735-6237 |
United States, New Jersey | |
MD Anderson Cancer Center at Cooper | Recruiting |
Camden, New Jersey, United States, 08103 | |
Contact: Kim Krieger 856-735-6237 |
Responsible Party: | The Cooper Health System |
ClinicalTrials.gov Identifier: | NCT02568033 |
Other Study ID Numbers: |
13-130 |
First Posted: | October 5, 2015 Key Record Dates |
Last Update Posted: | January 31, 2017 |
Last Verified: | July 2016 |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Paclitaxel Docetaxel Cisplatin Carboplatin |
Pemetrexed Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |